Table 1 Patient Characteristics
| Â | water | Age | gender | times | diagnosis | isodose curve (%) | total cGy | volume (cc) | collimater (cc) | response | Â | water | age | gender | times | diagnosis | isodose curve (%) | total cGy | volume (cc) | collimater (cc) | response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | placebo | 76 | M | 3 3 | HCC | 80 75 | 3,900 3,900 | 2.521 2.746 | 7.5 7.5 | NR | Â | HW | 52 | M | 3 | liver meta of colon ca | 74 | 3,600 | 12.283 | 15 | NR |
2 | placebo | 82 | M | 1 | HCC | 70 | 1,200 | 11.769 | 20 | CR | Â | HW | 56 | M | 3 | liver meta of colon ca | 85 | 3,600 | 2.552 | 12.5 | PR |
3 | placebo | 57 | F | 3 | bile duct ca | 80 | 3,000 | 40.334 | 30 | PR | Â | HW | 77 | F | 3 | liver meta of colon ca | 75 | 3,000 | 107.136 | 20 | CR |
4 | placebo | 47 | F | 9 | liver meta. of sarcoma | 80 82 84 | 3,600 3,600 3,900 | 10.628 6.542 2.673 | 25 20 15 | NR | Â | HW | 57 | M | 3 | HCC | 70 | 3,600 | 47.679 | 15 | NR |
5 | placebo | 50 | F | 3 | liver meta of colon ca | 80 | 3,900 | 16.237 | 20 | NR | Â | HW | 66 | M | 3 | HCC | 80 | 3,600 | 16.216 | 25 | PR |
6 | placebo | 21 | F | 3 | liver meta. of ovarian ca | 85 | 3,600 | 29.398 | 30 | CR | Â | HW | 57 | M | 3 | HCC | 80 | 3,600 | 35.303 | 30 | NR |
7 | placebo | 65 | M | 3 | liver meta. of rectal ca | 70 | 3,000 | 182.871 | 40 | PR | Â | HW | 47 | M | 3 | HCC | 77 | 3,000 | 17.65 | 20 | CR |
8 | placebo | 73 | M | 3 | liver meta. of rectal ca | 75 | 3,600 | 37.937 | 20 | PR | Â | HW | 49 | M | 3 | HCC | 80 | 3,300 | 53.578 | 12.5 | PR |
9 | placebo | 58 | M | 3 | liver meta. of pancreatic ca | 75 | 3,000 | 65.637 | 35 | CR | Â | HW | 71 | F | 3 | HCC | 85 | 3,000 | 3.861 | 10 | NR |
10 | placebo | 64 | M | 3 | HCC | 70 | 3,000 | 140.136 | 20 | PR | Â | HW | 45 | M | 3 | HCC | 80 | 3,600 | 28.286 | 15 | NR |
11 | placebo | 65 | F | 3 | HCC | 70 | 3,600 | 48.645 | 25 | PR | Â | HW | 45 | F | 3 | liver meta. of gastric ca | 85 | 3,000 | 38.938 | 15 | PR |
12 | placebo | 80 | M | 3 | HCC | 80 | 3,000 | 209.954 | 25 | NR | Â | HW | 56 | F | 3 | Adrenal metastasis of HCC | 80 | 3,600 | 9.494 | 15 | PR |
13 | placebo | 56 | M | 3 | HCC | 85 | 3,600 | 15.365 | 15 | CR | Â | HW | 49 | M | 3 | Adrenal metastasis of HCC | 75 | 3,000 | 91.223 | 20 | NR |
14 | placebo | 61 | F | 3 | HCC | 70 | 3,000 | 98.957 | 30 | NR | Â | HW | 60 | M | 3 | LN metastasis of HCC | 75 | 3,000 | 120.366 | 25 | NR |
15 | placebo | 46 | M | 3 | HCC | 80 | 3,000 | 20.848 | 25 | CR | Â | HW | 47 | M | 3 | LN metastasis of HCC | 80 | 3,000 | 80.459 | 25 | NR |
16 | placebo | 70 | F | 3 | HCC | 85 | 3,600 | 16.908 | 20 | PR | Â | HW | 50 | M | 3 | HCC | 75 | 3,600 | 29.422 | 20 | NR |
17 | placebo | 44 | M | 3 | HCC | 85 | 3,600 | 16.612 | 30 | NR | Â | HW | 49 | F | 3 | HCC | 70 | 3,000 | 156.289 | 40 | PR |
18 | placebo | 48 | M | 3 | HCC | 85 | 3,000 | 35.093 | 20 | NR | Â | HW | 63 | F | 3 | HCC | 75 | 3,900 | 5.425 | 20 | NR |
19 | placebo | 76 | F | 3 | HCC | 85 | 3,600 | 5.75 | 15 | NR | Â | HW | 51 | M | 3 | HCC | 70 | 4,000 | 28.637 | 35 | NR |
20 | placebo | 60 | M | 3 | HCC | 83 | 3,600 | 6.802 | 12.5 | NR | Â | HW | 67 | F | 3 | HCC | 80 | 3,600 | 20.122 | 20 | PR |
21 | placebo | 77 | M | 3 | HCC | 75 | 3,300 | 33.282 | 25 | PR | Â | HW | 56 | M | 3 | HCC | 70 | 3,600 | 23.5 | 20 | CR |
22 | placebo | 55 | M | 3 | HCC | 83 | 3,600 | 11.963 | 20 | NR | Â | HW | 78 | F | 3 | HCC | 83 | 3,600 | 26.456 | 25 | NR |
23 | placebo | 57 | M | 3 | HCC | 70 | 3,000 | 75.782 | 40 | NR | Â | HW | 56 | M | 3 | HCC | 77 | 3,600 | 31.908 | 20 | CR |
24 | placebo | 65 | M | 2 | HCC | 75 | 3,000 | 55.191 | 25 | NR | Â | HW | 60 | M | 3 | HCC | 70 | 3,600 | 36.479 | 30 | PR |
| Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | HW | 70 | M | 3 | HCC | 76 | 3,600 | 63.434 | 40 | NR |